Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 9/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448238 | 0.91 | NR1H2 (0.46) | NR1H2NR1H3TNNI3KBRAFEGFR | |
| SCHEMBL2449467 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3TNNI3K | |
| SCHEMBL3509582 | 0.89 | NR1H2 (0.61) | NR1H2NR1H3 | |
| SCHEMBL3506235 | 0.87 | NR1H2 (0.52) | NR1H2NR1H3 | |
| SCHEMBL2449124 | 0.87 | NR1H3 (0.48) | NR1H2NR1H3 | |
| SCHEMBL3508702 | 0.86 | NR1H2 (0.53) | NR1H2NR1H3 | |
| SCHEMBL3509877 | 0.82 | NR1H2 (0.51) | NR1H2NR1H3 | |
| SCHEMBL13363381 | 0.81 | NR1H2 (0.43) | NR1H2NR1H3 | |
| SCHEMBL3509016 | 0.81 | NR1H2 (0.46) | NR1H2NR1H3 | |
| SCHEMBL3506063 | 0.80 | NR1H2 (0.54) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981913-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981913-B2 | Liver X receptor (LXR) modulators | RALEXAR THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | RALEXAR THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-2367801-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | Wyeth LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214943-A1 | Liver X Receptor (LXR) Modulators | NR1H2, NR1H3, RXRB | NR1H2 1/4885NR1H3 2/4885TNNI3K 3817/4885 |
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | NR1H2 2/4885NR1H3 1/4885TNNI3K 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.